1805 related articles for article (PubMed ID: 21802721)
1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
; Davies C; Godwin J; Gray R; Clarke M; Cutter D; Darby S; McGale P; Pan HC; Taylor C; Wang YC; Dowsett M; Ingle J; Peto R
Lancet; 2011 Aug; 378(9793):771-84. PubMed ID: 21802721
[TBL] [Abstract][Full Text] [Related]
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
[TBL] [Abstract][Full Text] [Related]
5. WITHDRAWN: Tamoxifen for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000486. PubMed ID: 18843611
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1341-1352. PubMed ID: 26211827
[TBL] [Abstract][Full Text] [Related]
8. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C; Pan H; Godwin J; Gray R; Arriagada R; Raina V; Abraham M; Medeiros Alencar VH; Badran A; Bonfill X; Bradbury J; Clarke M; Collins R; Davis SR; Delmestri A; Forbes JF; Haddad P; Hou MF; Inbar M; Khaled H; Kielanowska J; Kwan WH; Mathew BS; Mittra I; Müller B; Nicolucci A; Peralta O; Pernas F; Petruzelka L; Pienkowski T; Radhika R; Rajan B; Rubach MT; Tort S; Urrútia G; Valentini M; Wang Y; Peto R;
Lancet; 2013 Mar; 381(9869):805-16. PubMed ID: 23219286
[TBL] [Abstract][Full Text] [Related]
10. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
; Darby S; McGale P; Correa C; Taylor C; Arriagada R; Clarke M; Cutter D; Davies C; Ewertz M; Godwin J; Gray R; Pierce L; Whelan T; Wang Y; Peto R
Lancet; 2011 Nov; 378(9804):1707-16. PubMed ID: 22019144
[TBL] [Abstract][Full Text] [Related]
11. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
; Clarke M; Coates AS; Darby SC; Davies C; Gelber RD; Godwin J; Goldhirsch A; Gray R; Peto R; Pritchard KI; Wood WC
Lancet; 2008 Jan; 371(9606):29-40. PubMed ID: 18177773
[TBL] [Abstract][Full Text] [Related]
13. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
14. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
15. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
16. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
17. WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000487. PubMed ID: 18843612
[TBL] [Abstract][Full Text] [Related]
18. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
20. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
